Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for URGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 2.186M
March 31, 2026 65.20M
December 31, 2025 33.34M
September 30, 2025 8.663M
June 30, 2025 0.2974M
March 31, 2025 0.034M
December 31, 2024 0.6463M
September 30, 2024 40.24M
June 30, 2024 99.05M
March 31, 2024 54.66M
December 31, 2023 -0.9864M
September 30, 2023 113.02M
June 30, 2023 0.1303M
March 31, 2023 0.671M
December 31, 2022 23.94M
September 30, 2022 0.5149M
June 30, 2022 -1.671M
March 31, 2022 70.74M
Date Value
December 31, 2021 1.235M
September 30, 2021 0.183M
June 30, 2021 72.64M
March 31, 2021 0.004M
December 31, 2020 0.3297M
September 30, 2020 0.3682M
June 30, 2020 16.27M
March 31, 2020 0.09M
December 31, 2019 -0.0498M
September 30, 2019 3.634M
June 30, 2019 1.472M
March 31, 2019 163.51M
December 31, 2018 1.658M
September 30, 2018 -0.3859M
June 30, 2018 -1.055M
March 31, 2018 64.26M
December 31, 2017 1.467M
September 30, 2017 -1.605M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Xencor, Inc. 1.031M
MeiraGTx Holdings Plc 133.89M
Insmed, Inc. 27.18M
Ironwood Pharmaceuticals, Inc. -199.70M
Viking Therapeutics, Inc. 23.59M